We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,335.00 | 1,333.50 | 1,334.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.22 | 55.34B |
Date | Subject | Author | Discuss |
---|---|---|---|
07/2/2022 13:00 | IN 2543 shares @ 1630.80 | tradermichael | |
07/2/2022 12:32 | Good point - the new techniques will add competition. | alphorn | |
07/2/2022 12:29 | Alp, one of the main concerns I have on the GSK pharma business is recent progress made by other companies on vaccine development. GSK may find their vaccine franchise facing significantly more competition on several fronts over the medium term?. Whether valid, you might have a better handle on. The flipside is rump pharma arguably an easier takeover target. | essentialinvestor | |
07/2/2022 12:25 | GlaxoSmithKline plc will announce its full year and fourth quarter 2021 results to the London Stock Exchange at 07:00 GMT on Wednesday 9 February 2022. Analysts and investors are invited to participate in a conference call and webcast, including a presentation of the results and a Q&A session. This event will take place on the same day at 14:00 GMT. To participate, please join the live audio webcast, which can be accessed directly via the website . The presentation will also be available on the website about one hour before the event's start. | tradermichael | |
07/2/2022 12:09 | Re. my earlier post on marking time - any damage to the pipeline will not show for some time (years). IMO this fuffing around over the group's future has been poorly handled. Sad to see, what was the UK's largest market cap, the group disappearing as it gets broken up. | alphorn | |
07/2/2022 12:04 | All depends on the company performance to be covered in the results on Wednesday. | tradermichael | |
07/2/2022 12:01 | No, spoole5, you should know by now that the drop (if any) on xd day is only temporary and often the price recovers some before close and in the following days! | tradermichael | |
07/2/2022 12:00 | Its not ex-dividend until 17 February! | tradermichael | |
07/2/2022 11:58 | It's already ex dividend. | southwinds | |
07/2/2022 11:57 | That should push it sub 16! | spoole5 | |
07/2/2022 09:17 | xd 23p per share next week .... ;0) | tradermichael | |
07/2/2022 08:17 | Dead money here until the split | spoole5 | |
06/2/2022 14:18 | TM yep my latest hope for lots of things THE SUM OF THE PARTS IS WORTH MORE THAN THE WHOLE | waldron | |
06/2/2022 13:56 | Marking time, correct. Early 2001 the share price topped 2000p. 21 years of no overall capital gain (though plenty of swings en route to make money by trading, propped up with lots of dividends). Here's relying on the 'split' to unlock capital from the 'sum-of-the-parts'! | tradermichael | |
06/2/2022 13:08 | The damage to the business in the interim could be huge as personnel consider their futures. I could imagine that the business is marking time. | alphorn | |
06/2/2022 12:59 | Not much different to the teenage scribblers of old. The demerger needs hurrying up. No doubt it's complicated but it seems to be taking an inordinate amount of time bearing in mind these managers are being paid millions of pounds a year. | patientcapital | |
06/2/2022 12:41 | Glaxo are only handing out £1.15bn (23p a share) as they have already paid out nearly £3bn in the first three quarters of this year. Not very good with detail these 'so called' financial reporters! | jonjoneil | |
06/2/2022 00:56 | GlaxoSmithKline and Unilever set to hand out combined £8bn in dividends, after suffering blistering attacks from US activist investors | philanderer | |
05/2/2022 15:26 | Broken up the pieces become more digestible. | alphorn | |
05/2/2022 15:18 | The takeover is out of the question as it is too big to purchase and it would certainly go through Monopoly Commission. The Govt don't want a repeat of ARM saga. | maxplus2 | |
03/2/2022 22:13 | I assume we will get more info about the timetable for the split in the results next week. | gateside | |
03/2/2022 16:05 | Not likely it's too close to GSK splitting time . | abdullla | |
03/2/2022 14:57 | Do they? Looks like retesting 1500s to me | spoole5 | |
03/2/2022 07:29 | Indeed, technicals looking very promising. All it needs is a couple of wins from Mr Barron’s drug delivery programme and it should be moving north at pace. Elliott will be pleased | daneswooddynamo | |
03/2/2022 02:12 | To all the moaners, remoaners and doubters can I refer you to the share price graph since March 2021. Way to go the Dame. More to come I suspect. | pcok |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions